Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pyxis Oncology Inc. Common Stock
PYXS | US
1.35
USD-0.14
-9.40%
PYXS | US
About Pyxis Oncology Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
05/03/2026
Close
1.35
Open
1.47
High
1.47
Low
1.34
Pyxis Oncology Inc. a clinical-stage biopharmaceutical company engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106 an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody which is in Phase 1 clinical trial for the treatment of solid tumors including non-small cell lung cancer (NSCLC) without driver mutations/translocations breast cancer endometrial cancer thyroid cancer kidney cancer cholangiocarcinoma bladder cancer colorectal cancer and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201 an investigational human immunoglobulin G1 isotype site-specifically conjugated which is in Phase 1 clinical trial for solid tumors including NSCLC hormone receptor-positive breast cancer ovarian cancer thyroid cancer pancreatic ductal adenocarcinoma soft tissue sarcoma hepatocellular carcinoma and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge Massachusetts.
View LessPYXS | US
Risk
74.7
Sharpe
0.12
Luna's Score
42/100
Recommendation
Sell
Luna says (PYXS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
90.9%1 month
74.7%3 months
147.3%6 months
137.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.31
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
1.09
Ent. to rev.
5.45
PEG
-
Other Fundamentals
EBITDA
-63.16M
MarketCap
80.22M
MarketCap(USD)
80.22M
Div. yield
-
Op. margin
-409.25
Erngs. growth
-
Rev. growth
-
Ret. on equity
-37.58
Short ratio
8.84
Short perc.
8.63
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.20
Range1M
0.42
Range3M
3.56
Volumes: Market Activity
Rel. volume
0.78
Price X volume
455.00K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.09 | 0.53 | Expensive |
| Ent. to Revenue | 5.45 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 147.25 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 80.22M | 3.66B | Emerging |
